How is the MMAE payload of brentuximab vedotin released inside tumour cells?

Non-clinical data suggest that brentuximab vedotin binds cell-surface CD30, triggering internalisation of the antibody–drug conjugate–CD30 complex and trafficking to the lysosomal compartment, where MMAE is released intracellularly via proteolytic cleavage.